Wells Fargo raises Cigna stock price target to $325 on valuation

Wells Fargo raised its price target for Cigna (CI) to $325 from $307, citing valuation, while lowering its 2027 and 2028 EPS estimates. Cigna's stock trades near its 52-week high. The company reported Q3 2026 earnings of $7.98 per share on $73.7B revenue, beating estimates. Analysts have mixed views on Cigna's future performance.

Original reporting
Published Nov 13, 2026, 10:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CI
Bullish
medium confidence
Mentioned
$CI
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CIBullishLow
01

Why it matters

The upgrade may prompt short‑term buying, but mixed analyst sentiment and lower earnings forecasts temper the upside.

02

Market read

Analyst target raise provides a modest trading signal for CI, with limited broader market effect.

03

What to watch

Piper Sandler's lower target of $360 highlights divergent views on pharmacy benefit margins.

Relevance 5/10Novelty 4/10Timing: today

Background

Wells Fargo increased its price target for Cigna (CI) to $325 while cutting 2027‑2028 EPS estimates, citing reduced discounting despite lower earnings forecasts.

Company-level read

Ticker impact

$CIBullishMedium confidence
Context

Wells Fargo raised its price target for Cigna to $325, indicating a more favorable valuation despite lower earnings estimates.

Expected impact

likely upward pressure as the market prices in the higher target

Evidence & confidence

Analyst price‑target upgrades often lead to short‑term buying interest, especially when the target exceeds current price.

Market effects

May lift sentiment in the health‑insurance sector as peers are re‑valued.

Limited to U.S. markets where Cigna trades.

Minimal global impact beyond U.S. health‑care investors.

Counterpoint

Target raise could be premature given lowered earnings forecasts and sector headwinds.

Key entities

  • Cigna

    U.S. health services insurer (ticker CI).

  • Wells Fargo

    Equity research firm raising CI price target.

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.